Lawmakers aim to prohibit companies from shifting their headquarters overseas in order to evade U.S. taxes, a measure that would apply retroactively to deals such as Medtronic's $43 billion acquisition of Covidien.
Covidien says it plans to launch the Emprint soft tissue ablation device for treating inoperable liver cancer during the 3rd quarter.
Covidien (NYSE:COV) said today that it's launching its Emprint soft tissue ablation system, aiming at the market for inoperable liver cancers.
Here's a look at some of the top regulatory stories for medical device companies this week: Shareholder files class action lawsuit to block Covidien-Medtronic merger; St. Jude drops $200M on NeuroTherm for spinal pain device; Allergan renews fight against hostile Valeant takeover; Abbott to deal pharma line to Mylan for $5.3B
Here's a look at some of the top legal news stories for medical device companies this week: Guidant can't slip breach-of-contract charges in Johnson & Johnson suit; Biomet reveals SEC subpoena over alleged 'improprieties' in Brazil, Mexico; Appeals court upholds Retractable Technologies win over Becton Dickinson; Board suspends ex-PricewaterhouseCoopers accountant over ArthroCare scandal; Covidien's Nellcor and CAS Medical settle dispute for $275k
, Becton Dickinson & Co.
, Boston Scientific
, CAS Medical Systems Inc.
, Dept. of Justice (DOJ)
, Guidant Corp.
, Johnson & Johnson
, Public Company Accounting Oversight Board
, Retractable Technologies Inc.
, Securities & Exchange Commission (SEC)
, Abbott Laboratories
Researchers use Intuitive Surgical's da Vinci robotic surgery system as a cautionary tale about the rapid adoption of new technologies that require physician training.
Covidien says its exposure to a raft of product liability lawsuits filed over pelvic mesh products increased by some $131 million during its fiscal 3rd quarter.
A Covidien shareholder files a purported class action lawsuit seeking to block the proposed, $43 billion merger of Medtronic and Covidien.